Enoxaparin sodium


Generic Medicine Info
Contraindications
Hypersensitivity to enoxaparin, heparin. Patients w/ active major bleeding, acute bacterial endocarditis, recent haemorrhagic stroke, active gastric or duodenal ulceration, thrombocytopenia associated w/ positive in vitro test for platelet antibodies.
Special Precautions
Patients w/ low body weight (women: <45 kg; men: <57 kg), bleeding diathesis, diabetic retinopathy, history of recent GI ulceration, history of heparin-induced thrombocytopenia, uncontrolled arterial HTN, or haemorrhage. Hepatic and renal impairment. Elderly, pregnancy and lactation. Monitoring Parameters Monitor patients for signs and symptoms of neurological impairment during treatment or immediately following diagnostic lumbar puncture, spinal or epidural anaesth. Periodic monitoring of CBC (e.g. platelet counts, stool occult blood tests). Monitor vascular access sites for signs of bleeding or haematoma during treatment.
Adverse Reactions
Haemorrhage (including at the inj site), peripheral or unspecified oedema, anaemia, haematuria, ecchymosis, fever, confusion, nausea, diarrhoea, dyspnoea, inj site pain.
Potentially Fatal: Major haemorrhagic complications (e.g. retroperitoneal and intracranial bleeding).
Drug Interactions
Increased risk of bleeding w/ anticoagulants, platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs, sulfinpyrazone). May increase bleeding w/ vit E.
CIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AB05 - enoxaparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.
Disclaimer: This information is independently developed by CIMS based on enoxaparin sodium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in